Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
Portfolio Pulse from
Lucid Diagnostics' EsoGuard® Esophageal DNA Test has shown high clinical utility with 85% patient compliance in a study accepted for publication. This marks the fourth peer-reviewed publication for the test, highlighting its effectiveness in cancer prevention diagnostics.
December 11, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lucid Diagnostics' EsoGuard® Test has demonstrated high clinical utility with 85% patient compliance, as reported in a new peer-reviewed study. This is the fourth publication highlighting the test's effectiveness.
The acceptance of the study for publication in a peer-reviewed journal and the high patient compliance rate are positive indicators of the test's clinical utility. This could enhance investor confidence and potentially lead to an increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Lucid Diagnostics, a subsidiary of PAVmed Inc., has had its EsoGuard® Test study accepted for publication, demonstrating high clinical utility. This reflects positively on PAVmed's investment in innovative diagnostics.
As the parent company of Lucid Diagnostics, PAVmed benefits from the positive results and publication of the EsoGuard® Test study, which could enhance its market position and investor sentiment.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70